Abstract
In this issue of Blood, Giarratana et al. provide an important proof of principle in the quest for biotechnology's equivalent of the Holy Grail of blood transfusion: ex vivo manufacture of human red cells (RBCs) for therapeutic use (see figure).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 5069-5070 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 118 |
| Issue number | 19 |
| DOIs | |
| State | Published - Nov 10 2011 |
| Externally published | Yes |
ASJC Scopus subject areas
- Hematology
- Biochemistry
- Cell Biology
- Immunology